September 2, 2020 -- The U.S. Food and Drug Administration (FDA) has granted an emergency use authorization to T2 Biosystems for its COVID-19 molecular diagnostic test, T2SARS-CoV-2 Panel.
The assay tests for the SARS-CoV-2 virus using nasopharyngeal swab samples and provides results in less than two hours. The panel runs on the company's FDA-cleared and automated T2Dx instrument, which can perform seven tests simultaneously. It demonstrated a sensitivity of 95% and specificity of 100% on both positive and negative patient samples, according to the company.
When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.Yes, Keep Me Current